Literature DB >> 9105236

compound A induces sister chromatid exchanges in Chinese hamster ovary cells.

E I Eger1, M J Laster, R Winegar, C Han, D Gong.   

Abstract

BACKGROUND: Compound A [CF2 = C(CF3)OCH2F], a degradation product of sevoflurane [(CF3)2CHOCH2F], is a vinyl ether and may be an alkylating agent. Thus it is a potential genotoxin.
METHODS: The capacity of compound A to produce sister chromatid exchanges was measured in Chinese hamster ovary cells with and without metabolic activation. Concentrations of 11 to 468 ppm compound A were applied for 2 h, the Chinese hamster ovary cells were incubated for a further 34 h in the presence of bromodeoxyuridine, and then colcemid was added to produce arrest in metaphase. Coded slides of cells were examined blindly, and 50 chromosome spreads were counted for each test concentration.
RESULTS: The lowest concentration of compound A applied without metabolic activator (27 ppm) significantly increased (P < 0.001) sister chromatid exchanges, and increasing concentrations of compound A increased the incidence of exchanges. Metabolic activation did not increase the incidence of exchanges.
CONCLUSIONS: Compound A increases sister chromatid exchanges at concentrations (27 ppm) obtained in low-flow systems when sevoflurane is used at concentrations approximating minimum alveolar concentration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9105236     DOI: 10.1097/00000542-199704000-00022

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  2 in total

Review 1.  Occupational exposure to volatile anaesthetics: epidemiology and approaches to reducing the problem.

Authors:  C Byhahn; H J Wilke; K Westpphal
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  RE: Yuge O: Renal toxicity of compound A with sevoflurane anesthesia: the benefits of sevoflurane appear to outweight the risks (editorial).J. Anesth 11:1-2.

Authors:  Edmond I Eger; Jackie L Martin
Journal:  J Anesth       Date:  1997-12       Impact factor: 2.078

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.